关注公众号，点击公众号主页右上角" ··· "，设置星标 "⭐" ，关注 鑫椤锂电 资讯~ 宁德时代方面表示， 本次募资所得的90%将投向匈牙利项目第一期及第二期建设， 进一步提升本地化供 应能力。目前宁德时代海外布局的产能主要包括德国工厂、匈牙利工厂、与Stellantis合资的西班牙工厂 及印尼电池产业链项目。 本文来源：储能前沿 宁德时代于2月11日正式向港交所递交A1申请文件，3月25日获中国证监会境外发行上市备案通知书，创 近年境外发行备案最快纪录。按照5月20日上市计算，宁德时代从申报到上市仅3月余。 宁德时代2024年营收为3620.13亿元，和上年同期相比（同比）减少9.70%；归属于上市公司股东的净 利润为507.45亿元，同比增加15.01%。值得一提的是，尽管净利润依然可观，但宁德时代在去年的营收 是自2018年上市以来首次出现同比下滑。 宁德时代的港股IPO正在如火如荼地进行中，目前展现出极高的市场热度。 2025年第一季度报告，宁德时代营收为847.05亿元，和上年同期相比（同比）增加6.18%；归属于上市 公司股东的净利润为139.63亿元，同比增加32.85%；综合毛利率达24. ...

近期，宁德时代在港股公开发售。截至5月14日，宁德时代已获得机构下单超500亿美元，折合约3902亿港元，剔除基石认购部分，已经超额认购30倍，有望 成为全球年度最大IPO。 突破保密上市要求 早在今年2月26日，香港特区政府财政司司长陈茂波就首次透露了"科企专线"。 陈茂波表示，为进一步协助特专科技和生物科企筹融资发展业务，特别是已在内地上市的公司，港交所正积极筹备开通"科企专线"，便利有关企业的上市申 请准备工作。香港证监会亦会配合，令申请过程更畅顺。 不到三个月时间，"科企专线"正式落地。 据了解，"科企专线"旨在帮助有意来港上市的特专科技公司及生物科技公司在提交正式的上市申请之前理解适用的《上市规则》及进行相关的上市筹备工 作，包括就上市资格及合适性提供指引，例如核心产品要求、是否接受其他生物科技产品及/或不同药监机构监管的临床试验、资深投资者的资格及独立 性、特专科技行业可接纳领域，以及接纳当前范围以外的其他新领域/行业为特专科技行业的考虑因素等。 "'科企专线'是面向拟赴港上市的特专科技公司及生物科技公司设置的专门沟通渠道，配备了经验丰富的专业团队，为拟上市企业在提交上市申请前即提供 专门的指引， ...

据迈威生物公告，公司收到公司董事长兼总经理刘大涛通知，其于近日收到中国证监会出具的《立案告知书》(编号：证监立案字 0032025019号)，因涉嫌短线交易，中国证监会根据《中华人民共和国证券法》《中华人民共和国行政处罚法》等法律法规，决定对其立 案。 本次事项系对刘大涛个人的调查，不会对公司日常经营活动产生重大影响，立案调查期间，刘大涛将积极配合中国证监会开展调查工作。 值得注意的是，迈威生物正值冲刺港股上市的关键期。2024年12月16日，迈威生物公告称，为满足公司经营发展的资金需求，实现公司可持 续发展，提升公司国际化水平，公司拟在境外发行股份(H股)并在香港联交所主板上市，公司将在股东大会决议有效期内选择适当的时机和 发行窗口完成本次发行H股并上市。截至目前，公司正积极与相关中介机构就本次发行H股并上市的相关工作进行商讨，除本次董事会审议 通过的相关议案外，其他关于本次发行H股并上市的具体细节尚未确定。本次发行H股并上市是否能通过审议和审核/备案程序并最终实施具 有重大不确定性。 中国经济网北京5月13日讯迈威生物(688062.SH)近日发布了关于公司董事长兼总经理收到立案告知书的公告。 中国经济网 ...

Wind资讯数据显示，截至5月12日《证券日报》记者发稿，状态为"聆讯通过"的拟上市公司有5家，状 态为"处理中"的拟上市公司逾150家。"A+H"趋势愈发明显，企业业态持续丰富。 继赤峰吉隆黄金矿业股份有限公司、海南钧达新能源科技股份有限公司这两家A股公司顺利在港上市之 后，宁德时代成为年内第三家赴港上市成行的A股公司。 5月12日，宁德时代新能源科技股份有限公司（以下简称"宁德时代"）披露发行阶段董事会公告及刊登 注册招股书，宣布正式启动国际配售簿记，预计于5月20日在香港联交所主板挂牌并开始上市交易。按 发行价格上限263港元/股计算，本次港股IPO发行规模预计达40亿美元至50亿美元。 同日，宁德时代正式开启认购。老虎证券数据显示，截至当天18时，宁德时代的市场融资申购额已超 468.8亿港元，认购倍数约20.15倍。 此前，有多只新股获得超额认购。例如，5月8日上市的沪上阿姨（上海）实业股份有限公司（以下简 称"沪上阿姨"）申购倍数达到3616，申购额超过940亿港元。3月3日，蜜雪冰城股份有限公司（以下简 称"蜜雪集团"）以超5258倍的认购倍数、1.84万亿港元的认购金额刷新港股史上新股认购纪录 ...

Group 1: IPO Market Overview - The number of companies applying for IPOs in Hong Kong is increasing, with 130 applications currently under review as of April 30, and 19 companies already listed [1][2] - In May alone, 8 companies have submitted applications, with 4 companies applying on May 9 [2][3] Group 2: Featured Companies - Tongshifu, a new consumption company, ranks first in China's copper cultural products market with a market share of 35% and an average online transaction value exceeding RMB 750 [3][4] - Zhejing Electronics, a hard technology company, has seen a 3-fold increase in solution delivery from FY2022 to FY2024, with a compound annual growth rate of 64.3% [4][5] - Zhongding Intelligent, a provider of smart logistics solutions, ranks fourth in the overall market and first in the lithium-ion battery sector in China [5] - Fuyou Payment, a digital payment technology platform, ranks eighth in China's comprehensive digital payment service providers with a market share of 0.8% [5] Group 3: Market Trends and Predictions - The Hong Kong IPO market is experiencing a resurgence, with 17 companies listed in Q1 2024, raising a total of HKD 18.7 billion, nearly four times the amount from Q1 2023 [7][8] - The upcoming IPO of CATL is expected to raise approximately HKD 30.7 billion, potentially surpassing the previous record set by Midea Group [7][8] - Factors driving the recovery of the IPO market include advancements in AI technology, improved liquidity due to the Federal Reserve's interest rate cuts, and a noticeable profit-making effect from new listings [8]

Core Viewpoint - The number of companies applying for listing in Hong Kong is increasing, indicating a robust IPO market. In May alone, eight companies submitted applications, with four doing so on May 9 [1][4]. Group 1: Listing Applications - As of April 30, there are 130 companies with applications under review, 19 companies have been listed, and 18 are awaiting listing approval [2][3]. - In April, the Hong Kong Stock Exchange received applications from 32 main board companies, 3 GEM companies, and 7 companies under Chapter 20 of the Main Board Listing Rules [3]. Group 2: Featured Companies - The companies applying for listing are primarily focused on "hard technology + new consumption." For instance, Tong Shifu is a new consumption company leading in the Chinese copper cultural and creative product market with a market share of 35% [6][8]. - Zhejing Electronics is a hard technology company specializing in smart cockpit visual and interaction solutions, with a revenue compound annual growth rate (CAGR) of 64.3% from FY2022 to FY2024 [8][9]. - Zhongding Intelligent is a leading provider of smart in-warehouse logistics and automation solutions, ranking fourth in the overall market and first in the new energy lithium-ion battery sector [11][12]. - Fuyou Payment, while not as highly ranked, is a versatile digital payment technology platform, holding an 0.8% market share in China's comprehensive digital payment service market [12]. Group 3: IPO Market Dynamics - The Hong Kong IPO market is experiencing a resurgence, with 17 companies listed in Q1 2024, raising a total of HKD 18.7 billion, nearly four times the amount from Q1 2023 [14]. - The upcoming IPO of CATL is expected to raise approximately HKD 30.7 billion, potentially surpassing the previous record set by Midea Group [16]. - Factors driving the recovery of the IPO market include breakthroughs in AI technology, improved liquidity due to the Federal Reserve's interest rate cuts, and a noticeable profit-making effect from new listings [17].

Summary of Key Points Core Viewpoint The Hong Kong IPO market has seen significant activity from May 5 to May 11, with 8 companies submitting applications, 3 companies passing hearings, 1 company going public, and 3 companies listing. Group 1: IPO Applications - A total of 8 companies submitted IPO applications, including Zhongqi Yunlian, MIRXES, YS Intelligent, Xidi Zhijia, Tong Shifu, Zhejing Electronics, Zhongding Integration, and Fuyou Payment [2][3] - Zhongqi Yunlian, established in 2015, is a leading independent digital financial platform in China, with a projected revenue of 6.52 billion RMB in 2022, increasing to 9.91 billion RMB by 2024 [3] - MIRXES, founded in 2014, specializes in miRNA technology for disease screening, with projected revenues of approximately 177.59 million USD in 2022, growing to 202.83 million USD by 2024 [4][5] - YS Intelligent, focusing on AI-driven pharmaceutical solutions, has raised over 500 million USD from notable investors and has a post-money valuation of 1.33 billion USD [6] - Xidi Zhijia, a provider of autonomous driving solutions, reported revenues of 310.56 million RMB in 2022, expected to reach 410 million RMB by 2024 [7] - Tong Shifu, established in 2013, leads the copper cultural products market in China with a 35% market share, projecting revenues of 503 million RMB in 2022 [8] - Zhejing Electronics, a pioneer in smart cockpit solutions, reported revenues of approximately 214 million RMB in 2022, with expectations of growth [9] - Zhongding Integration, a provider of smart logistics solutions, reported revenues of approximately 1.643 billion RMB in 2022, with a projected increase [11] - Fuyou Payment, a digital payment technology platform, reported revenues of approximately 1.142 billion RMB in 2022, with growth anticipated [12] Group 2: Companies Passing Hearings - Heng Rui Pharmaceutical, a leading innovative pharmaceutical company, reported revenues of 21.275 billion RMB in 2022, expected to grow to 27.985 billion RMB by 2024 [13][14] - Ningde Times, a leader in battery manufacturing, is expected to raise between 4 billion to 5 billion USD in its IPO, with a market share of 37.9% in the global battery market by 2024 [15][16] - Jihong Co., a dual-driven company in cross-border e-commerce and paper packaging, reported revenues of 5.376 billion RMB in 2022, with growth expected [17] Group 3: IPO and Listings - Green Tea Group is set to launch its IPO, offering 168 million shares at a price of 7.19 HKD per share, with significant interest from cornerstone investors [18] - Boleton, listed on May 7, priced at 18 HKD per share, saw a closing price of 24.9 HKD, reflecting a 38% increase [19] - Hu Shang Ayi, listed on May 8, had an opening price of 190.6 HKD, closing at 158.4 HKD, a 40.03% increase from its issue price [20] - Jun Da Co., also listed on May 8, opened at 22.2 HKD and closed at 26.6 HKD, marking a 20.09% increase [20] Group 4: Market Developments - The Hong Kong Stock Exchange has launched a "Tech Company Fast Track" to facilitate IPO applications for technology and biotech companies, allowing for confidential submissions [21]

本文为IPO早知道原创 作者｜ Stone Jin 微信公众号｜ipozaozhidao 据 IPO早知道消息， 宁德时代新能源科技股份有限公司 （以下简称 " 宁德时代 "）今起招股、至 15日结束，并计划于2025年5月20日正式以"3570"为股票代码在港交所挂牌上市。 宁德时代 本次计划发行 117,894,500股H股 。其中，香港公开发售 8,842,100股H股 ，国际发售 109,052,400股H股 。以每股 263港元的发行价计算， 宁德时代 将通过本次发行募集 307.18亿 港元（约39.41亿美元）。 这意味着， 宁德时代 将成为继 2021年的快手后，4年多以来最大的港股IPO 。 在本次发行中， 宁德时代 引入中石化、科威特投资局、高瓴、高毅投资、兰馨亚洲、博裕资本、景 林投资、 保银资本 、 WT Funds 、 CPE 源峰、 Oaktree 、元生资本、 Mirae Asset 、 加皇环 球资产管理 、太平洋保险、 LMR Partners 、 洛阳科创集团 、 中 邮 、 泰 康 人 寿 、 Lingotto Investment Management 等数十位投资者累 ...

Core Viewpoint - The company, Maiwei Biotech, is under investigation by the China Securities Regulatory Commission (CSRC) for suspected short-term trading involving its chairman and general manager, Liu Datao, but this investigation is stated to not significantly impact the company's daily operations [1] Group 1: Company Overview - Maiwei Biotech is an innovative biopharmaceutical company with a full industry chain layout, focusing on products such as antibodies, ADC drugs, recombinant proteins, and small molecule chemical drugs [3] - The company has not yet achieved profitability and has accumulated losses exceeding 3 billion yuan over the past three years [5] Group 2: Financial Performance - From 2022 to 2024, the company's net profits were reported as -955 million yuan, -1.053 billion yuan, and -1.044 billion yuan respectively, indicating consistent losses [5] - In 2024, the company achieved approximately 200 million yuan in revenue, representing a year-on-year growth of 56.28%, while still reporting a net loss of 1.044 billion yuan [5] Group 3: Funding and Market Position - Maiwei Biotech was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board in January 2022, raising a net amount of 3.303 billion yuan [7] - The company is currently advancing its IPO process in Hong Kong, having submitted an application to the Hong Kong Stock Exchange for H-share listing on January 6, 2025 [7] - As of May 9, the company's stock price closed at 19.99 yuan per share, with a total market capitalization of 7.988 billion yuan [7]

Group 1 - The core viewpoint of the article highlights the contrasting IPO trends between A-shares and Hong Kong stocks, with the latter experiencing a surge in IPO activities due to the introduction of the "Specialized Technology Company Line" [2][4][10] - The "Specialized Technology Company Line" policy aims to facilitate the listing process for specialized technology and biotechnology companies, allowing them to submit applications confidentially, which is expected to alleviate the exit difficulties faced by investors in the primary market [3][6][8] - The Hong Kong Stock Exchange has seen a significant increase in IPO activities, with 17 companies listed in the first quarter of 2025, raising a total of HKD 18.7 billion, nearly four times the amount raised in the first quarter of 2024 [11][12] Group 2 - The introduction of the "Specialized Technology Company Line" is viewed as a major benefit for early-stage companies, as it reduces the risk of sensitive information leakage and enhances the autonomy of companies preparing for listing [8][14] - The new policy is expected to attract more high-quality companies to list in Hong Kong, reshaping the capital market landscape, particularly for innovative sectors like biotechnology [14]